Use of cyclosporine pharmacokinetic profiles in an antibody induction protocol reduces early acute rejection rates in recipients of primary cadaveric renal allografts
- 1 February 1997
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 29 (1-2) , 294-295
- https://doi.org/10.1016/s0041-1345(96)00113-3
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- A study of the quality of life and cost-utility of renal transplantationKidney International, 1996
- Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine eraClinical Transplantation, 1996
- Strategies to improve the immunologic management of organ transplantsClinical Transplantation, 1995
- Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantationClinical Pharmacology & Therapeutics, 1993
- Antilymphocyte Globulin Versus OKT3 Induction Therapy in Cadaveric Kidney Transplantation: A Prospective Randomized StudyAmerican Journal of Kidney Diseases, 1992
- THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTSTransplantation, 1992
- OPTIMIZATION OF CYCLOSPORINE THERAPY IN RENAL TRANSPLANTATION BY A PHARMACOKINETIC STRATEGYTransplantation, 1988
- SERUM CYCLOSPORINE KINETIC PROFILETransplantation, 1988